Mission

Mission

Discover unutilized innovative drug seeds in Japan

We discover innovative intellectual property, research result, and know-how that has been unutilized in Japanese pharmaceuticals, biotech companies, and academia and advance them into the early stage of drug development (non-clinical studies and early-phase clinical trials).

Develop novel medicines for refractory diseases

We develop novel medicines for refractory diseases (mainly immune-mediated diseases) and deliver them to patients in the world.

Vision

The recent global open innovation trend highlighted the following problems in drug discovery in Japan:

  1. Unutilized innovative drug seeds

    Recently, many Japanese pharmaceutical companies have made a strategic review of focused therapeutic areas and terminated research and development programs in non-focused therapeutic areas. Accordingly, a number of promising drug seeds is left unused in Japan.
  2. Lack of a professional team specialized in early stage of drug development

    Under immature venture business environment in Japan, biotech companies and academia do not have access to sufficient funds and expertise on drug development. Therefore, it is quite difficult for them to conduct the development of non-clinical studies (including the studies belonging to GLP*) through early-phase clinical trials. Under such circumstances, to deliver novel medicines to patients, a company with expertise in early stage of drug development is particularly required.

Curadim Pharma was established to solve these problems. We discover unutilized innovative drug seeds in Japan and enhance the flow of drug development as a company specialized in conducting the early stage of drug development (non-clinical studies and early-phase clinical trials). Through providing such solutions, we are committed to deliver treatments for refractory diseases with high unmet medical needs to patients in the world.

*An abbreviation of “Good Laboratory Practice,” which refers to standards for ensuring reliability of data by appropriately conducting non-clinical safety studies.

Our Vision (Future of Drug Development Environment in Japan)

Our Vision (Future of Drug Development Environment in Japan) Our Vision (Future of Drug Development Environment in Japan)

Specialized company in early stage of drug development
(non-clinical studies and early-phase clinical trials)

  • Acquire promising drug seeds that are terminated by change in focused therapeutic area or seek repositioning or expanding of indication to non-focused therapeutic area.
  • Succeed innovative drug seeds from pharmaceuticals, biotech company, and academia that have not experienced in global drug development.